Genomics in Michigan to AdJust Outcomes in Prostate canceR (G-MAJOR) for Men With Newly Diagnosed Favorable Risk Prostate Cancer
NCT04396808 · Status: ACTIVE_NOT_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 805
Last updated 2026-04-15
Summary
This study seeks to determine the clinical impact of Gene Expression Classifier (GEC) testing in prostate cancer care while also developing a pragmatic approach for improved GEC clinical use and future study.
Conditions
Interventions
- OTHER
-
Standard of care (askMUSIC score)
AskMUSIC is a risk calculator based on standard clinical and pathologic variables (https://ask.musicurology.com/) and is generally included as part of routine clinical care.
- DEVICE
-
Oncotype Dx Genomic Prostate Score (GPS)
The Oncotype Dx GPS test (Exact Sciences corp.) is a genomic test that will be performed on prostate biopsy tissue. Results will be provided to the patient and physician prior to making a treatment decision.
- DEVICE
-
Decipher
The Decipher test (GenomeDx Biosciences) is a genomic test that will be performed on prostate biopsy tissue. Results will be provided to the patient and physician prior to making a treatment decision.
- DEVICE
-
Prolaris
The Prolaris test (Myriad Genetics, Inc.) is a genomic test that will be performed on prostate biopsy tissue. Results will be provided to the patient and physician prior to making a treatment decision.
Sponsors & Collaborators
-
MDx Health
collaborator INDUSTRY -
National Cancer Institute (NCI)
collaborator NIH -
National Institutes of Health (NIH)
collaborator NIH -
Myrexis Inc.
collaborator INDUSTRY -
Veracyte, Inc.
collaborator INDUSTRY -
University of Michigan Rogel Cancer Center
lead OTHER
Principal Investigators
-
Todd Morgan, M.D. · University of Michigan
-
Daniel Spratt, M.D. · University of Michigan
Study Design
- Allocation
- RANDOMIZED
- Purpose
- OTHER
- Masking
- NONE
- Model
- CROSSOVER
Eligibility
- Min Age
- 18 Years
- Sex
- MALE
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2020-11-05
- Primary Completion
- 2028-03-31
- Completion
- 2031-03-31
Countries
- United States
Study Locations
More Related Trials
-
Integrated Genomic Prostate Score With MRI Targeted Prostate Biopsies
NCT04541030 ·Status: ACTIVE_NOT_RECRUITING
-
Evaluation of a Multimodal Strategy for Early Diagnosis of Men at High Genetic Risk of Prostate Cancer
NCT05333432 ·Status: WITHDRAWN ·Phase: NA
-
Prostate Cancer Genetic Risk Evaluation and Screening Study
NCT05129605 ·Status: RECRUITING
-
Microarray Analysis of Gene Expression in Prostate Tissues
NCT00186368 ·Status: COMPLETED
-
Analysis of Androgene Receptors Axis and DNA Damage Repair Genes in Patients With Prostate Cancer
NCT03677414 ·Status: UNKNOWN
-
Trial of Prostate Cancer Patients Undergoing Active Surveillance With or Without MRI-Guided Management
NCT01838265 ·Status: WITHDRAWN
-
Performance of Inherited Risk Assessment for Predicting Prostate Cancer From Prostate Biopsy
NCT05295407 ·Status: RECRUITING
-
PROCLAIM: Germline Genetic Testing for Prostate Cancer Patients
NCT05447637 ·Status: COMPLETED
-
Prostate Cancer Upgrading Reference Set
NCT02189486 ·Status: COMPLETED
-
Clinical Utility of MyProstateScore 2.0 P2
NCT05910697 ·Status: TERMINATED ·Phase: NA
-
Micro-RNA Expression Profiles in High Risk Prostate Cancer
NCT01220427 ·Status: TERMINATED
-
Understanding of Genetics by Men at Risk for Prostate Cancer
NCT04550845 ·Status: RECRUITING ·Phase: NA
-
INSIDE: Identification of Genomic Screening Pathways in Cancer Patients With DNA Repair Alterations
NCT06334809 ·Status: RECRUITING
-
Screening for Prostate Cancer Using High Resolution Micro-ultrasound Versus Multiparametric Magnetic Resonance Imaging.
NCT06626022 ·Status: RECRUITING ·Phase: PHASE3
-
MRI-Based Active Surveillance to Avoid the Risks of Serial Biopsies in Men With Low-Risk Prostate Ca
NCT02564549 ·Status: TERMINATED ·Phase: NA
-
MyProstateScore Equivalency With and Without DRE
NCT05700370 ·Status: UNKNOWN ·Phase: NA
-
Evaluation of a Targeted Magnetic Resonance Imaging Contrast Agent in Prostate Cancer Patients
NCT06262139 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Clinical Validation of a Urinary Exosome Gene Signature in Men Presenting for Suspicion of Prostate Cancer
NCT02702856 ·Status: COMPLETED
-
The PROFILE Study: Germline Genetic Profiling: Correlation With Targeted Prostate Cancer Screening and Treatment
NCT02543905 ·Status: RECRUITING
-
MRI And GPS Informing Choices for Prostate Cancer Treatment (MAGIC)
NCT05424783 ·Status: RECRUITING
-
Identify Genes/Pathways Responsible for Progression From Low Risk to Higher Risk Prostate Cancer
NCT03789253 ·Status: RECRUITING
-
Optimizing Active Surveillance in Low-Risk Prostate Cancer: a Pilot Study
NCT05764005 ·Status: COMPLETED ·Phase: NA
-
Long-Term Prospective Registry in Prostate Cancer Patients From Diverse Urology Practice Settings Following Prolaris® Testing
NCT04404894 ·Status: ACTIVE_NOT_RECRUITING
-
MRI Screening in Men at High Risk of Developing Prostate Cancer
NCT05608694 ·Status: RECRUITING ·Phase: NA
-
Genetic Biomarker Discovery for Metastatic Prostate Cancer
NCT03228810 ·Status: COMPLETED